Reuters -- Older breast cancer patients who got Roche AG’s (ROG.VX) drug Xeloda all by itself were almost twice as likely to relapse and die than women who got standard chemotherapy, U.S. researchers reported on Wednesday.
Reuters -- Older breast cancer patients who got Roche AG’s (ROG.VX) drug Xeloda all by itself were almost twice as likely to relapse and die than women who got standard chemotherapy, U.S. researchers reported on Wednesday.
